CKM Syndrome: Why Heart, Kidney, and Metabolic Health Cannot Be Separated

For years, Dr. Retzler and I have talked with patients about the same pattern showing up again and again. Blood pressure is treated in one lane. Cholesterol in another. Weight in another. Blood sugar somewhere else. Kidney function may not get much attention until it is clearly abnormal.

But the body does not work in separate departments.

That is why the new cardiovascular-kidney-metabolic syndrome guideline matters. Not because it suddenly discovered something new overnight, but because it formally recognizes what many of us in longevity and preventive medicine have been watching for years: the heart, kidneys, and metabolism are one connected system.

On June 9, 2026, the American Heart Association, American College of Cardiology, American Diabetes Association, and American Society of Nephrology issued the first clinical practice guideline on cardiovascular-kidney-metabolic syndrome, or CKM syndrome. The guideline was published in Circulation and JACC.

The headline number is hard to ignore. According to the American Heart Association release, nearly 90% of U.S. adults have at least one CKM risk factor, including excess weight, high blood pressure, abnormal lipids, high blood glucose, or reduced kidney function.

That does not mean nearly 90% of adults have advanced disease. It means the early warning signs are common, and many of them are showing up long before a heart attack, stroke, kidney failure, or diagnosis of diabetes.

What CKM Syndrome Means

CKM syndrome is a framework for understanding how cardiovascular disease, kidney disease, and metabolic dysfunction influence one another. It is not just a new label. It is an attempt to move medicine away from treating isolated numbers and toward recognizing connected risk earlier.

The guideline outlines stages of CKM risk, moving from early metabolic risk to established cardiovascular disease with metabolic and kidney involvement. That staging matters because it gives clinicians a way to act before the crisis. A person does not need to wait until they have chest pain, a stroke, heart failure, or kidney decline before prevention becomes serious.

This is where the conversation has been moving for a long time. Metabolic health is not cosmetic. Kidney function is not a side note. Blood pressure is not just a number to watch once a year. Body composition, visceral fat, glucose regulation, lipids, inflammation, sleep, muscle, and vascular health all belong in the same clinical conversation.

The HormoneSynergy Perspective

At HormoneSynergy®, this is exactly why we do not evaluate cardiovascular risk by looking at one number on a lab report.

LDL cholesterol matters. ApoB matters. Blood pressure matters. Glucose matters. Kidney function matters. Body composition matters. Sleep, inflammation, visceral fat, insulin resistance, hormone transitions, family history, and vascular imaging all matter too.

The issue is not whether any one marker is important. The issue is whether the pattern is being understood early enough to change the direction of care.

This is especially relevant for patients who have been told that everything looks “normal” while they are gaining visceral fat, losing muscle, becoming more insulin resistant, developing higher blood pressure, seeing triglycerides creep up, or noticing lower energy and recovery. Those early shifts may not feel dramatic at first, but they can be part of the same cardiometabolic story.

CKM syndrome gives mainstream medicine a more formal language for that story.

Why This Is Not Just About Diabetes

One important shift in the guideline is the recognition that certain medications may be used for broader cardiometabolic and kidney protection in appropriate patients, not only for glucose lowering.

That includes GLP-1-based therapies for select individuals with obesity and/or type 2 diabetes and cardiovascular risk factors, and SGLT2 inhibitors in appropriate clinical contexts. This does not mean everyone needs medication. It does mean the conversation has changed.

For years, medications like these were often discussed narrowly as diabetes or weight-loss drugs. The CKM framework places them in a broader clinical context: cardiometabolic risk, kidney protection, cardiovascular outcomes, and earlier intervention when the risk pattern supports it.

That distinction matters. At HormoneSynergy, we are not interested in turning every patient into a prescription. We are interested in understanding the person in front of us well enough to know when lifestyle is enough, when deeper testing is needed, and when medication may be an appropriate tool as part of a larger plan.

That is especially true with GLP-1 therapy. Weight loss alone is not the goal. The goal is improved metabolic health, preserved muscle, better insulin sensitivity, lower cardiometabolic risk, and a plan that can actually be sustained.

Learn more about our medically supervised approach here: GLP-1 Weight Loss for Longevity™.

Prevention Has to Start Before Disease Announces Itself

One of the biggest problems in conventional medicine is that too much care begins after the diagnosis is obvious.

A person may be told they are fine because their fasting glucose is not yet diabetic, their kidney function is technically in range, their cholesterol is not alarming enough to trigger action, or their blood pressure is only mildly elevated. But when those findings appear together, especially alongside visceral fat, poor sleep, declining muscle, inflammation, family history, or early vascular changes, they may represent a pattern worth taking seriously.

This is where longevity medicine and preventive cardiology overlap.

The question is not simply, “Do you have disease?”

The better question is, “What direction is your biology moving?”

That is why we use tools such as advanced labs, body composition testing, vascular screening, DEXA when appropriate, and cardiometabolic risk assessment to look at the larger picture.

Relevant HormoneSynergy Resources

• Longevity Medicine & Healthspan at HormoneSynergy
• Cleerly® Testing and Preventive Cardiology in Portland and Lake Oswego
• DEXA Body Composition and Bone Density Testing
• ApoB and Longevity: Cardiovascular Risk and Lipoprotein Particles
• More Testing Is Not More Medicine

What This Guideline Does Not Prove

It is important not to overstate the news.

This is a clinical practice guideline, not a brand-new trial. It synthesizes existing evidence and provides a framework for screening, staging, prevention, and treatment. It does not prove that the staging system itself will reduce heart attacks, strokes, kidney failure, or mortality. That will depend on implementation, patient selection, clinical judgment, access to care, and follow-through.

That said, the direction is important.

Medicine needs better pattern recognition. It needs earlier risk identification. It needs to stop pretending that metabolic health, kidney health, and cardiovascular health can be separated into clean little boxes.

They cannot.

The Real Takeaway

The CKM guideline is a welcome correction in how risk is framed.

It recognizes that excess weight, insulin resistance, abnormal lipids, high blood pressure, reduced kidney function, and cardiovascular disease often travel together. It also recognizes that prevention should not wait until the most serious outcome appears.

At HormoneSynergy, this is the work we care about most: helping patients understand risk earlier, protect capacity longer, and make decisions based on the full clinical picture rather than one isolated number.

The heart is not separate from the kidneys. The kidneys are not separate from metabolism. And metabolism is not separate from the way a person sleeps, eats, moves, builds muscle, handles stress, responds to hormones, stores fat, and ages over time.

That is not a trend. That is biology.

FAQ

What is cardiovascular-kidney-metabolic syndrome?

Cardiovascular-kidney-metabolic syndrome, or CKM syndrome, is a clinical framework that recognizes the connection between heart disease, kidney disease, and metabolic dysfunction. It includes risk factors such as excess weight, abnormal blood sugar, high blood pressure, abnormal lipids, and reduced kidney function.

Does having one CKM risk factor mean I have advanced disease?

No. Having one risk factor does not mean someone has advanced cardiovascular, kidney, or metabolic disease. It means there may be an early opportunity to identify risk, improve lifestyle, assess the larger pattern, and intervene before more serious disease develops.

Why does kidney function matter for heart disease prevention?

Kidney function and cardiovascular health are closely connected. Reduced kidney function can increase cardiovascular risk, and high blood pressure, diabetes, inflammation, and vascular disease can all affect kidney health over time.

Are GLP-1 medications now considered heart-protective?

The CKM guideline recognizes GLP-1-based therapies as an option for select individuals with obesity and/or type 2 diabetes and cardiovascular risk factors. These medications are not appropriate for everyone, and they should be considered within a complete medical plan that includes nutrition, muscle preservation, lifestyle, monitoring, and individualized risk assessment.

How does HormoneSynergy evaluate CKM risk?

HormoneSynergy evaluates cardiometabolic risk by looking at the broader pattern, including blood pressure, lipids, glucose and insulin markers, kidney function, body composition, visceral fat, vascular testing when appropriate, sleep, inflammation, hormone status, family history, and lifestyle patterns.